IHS-TOWERS
12.4.2021 08:02:13 CEST | Business Wire | Press release
IHS Holding Limited (“IHS Towers”), one of the largest independent owners, operators and developers of shared telecommunications infrastructure in the world by tower count, has acquired Centennial Towers’ Brazilian and Colombian tower operations.
This acquisition brings an additional 602 towers in Brazil, and 217 towers in Colombia, strengthening IHS Towers’ position and core expertise in both markets. This latest transaction comes shortly after IHS Towers’ acquisition of Skysites in Brazil and is a testament to the company’s commitment to expanding its business in both Latin American markets. Centennial Towers has extensive expertise in providing mobile network operators with a wide range of infrastructure solutions including Build to Suit towers, Rooftops, Distributed Antenna Systems, Small Cells and Site Colocation & Leasing.
These recent acquisitions highlight and demonstrate the continuation of IHS Towers’ growth strategy and demonstrates its 20-year track record of growth and excellence in telecommunications infrastructure across emerging markets. IHS Towers has developed complete ecosystems around its towers including green energy, backhaul, monitoring and active equipment which will be leveraged across its new Latin American markets. This acquisition will further enhance IHS Towers’ customer offerings and ensure the company is well-positioned to support the upcoming roll-out of 5G by offering customers new locations for signal transmission and distribution, as well as supporting fiber deployment.
Sam Darwish, IHS Chairman and Group Chief Executive Officer , said: “Following our recent acquisition of Skysites in Brazil, I am delighted to announce the acquisition of a third Latin American tower operator. The addition of Centennial Towers’ Brazilian and Colombian operations adds scale to our IHS Towers Latin American portfolio and will further strengthen the deep expertise and solutions we can offer to current and potential customers in these markets. Latin America remains a key region for us with its high growth potential and, through these transactions, we will continue to increase our market presence and build on the momentum sparked by our initial entry into the region last year with the acquisition of Cell Site Solutions.”
Steven Moskowitz, Chief Executive Officer, Centennial Towers, said: “We are thrilled to enter into this transaction with IHS Towers as they recognize the uniqueness of Centennial’s diverse asset base in these two countries, which are primed for high levels of growth due to their strategic locations and quality construction. Centennial’s strong client relationships and proprietary management information systems will assist IHS Towers in advancing their drive to significantly increasing footprint and colocation growth in Latin America for years to come.”
About IHS: IHS is one of the largest independent owners, operators and developers of shared telecommunications infrastructure in the world by tower count, with more than 29,700 towers across nine markets. IHS continues to grow and develop its existing positions and offerings in Brazil, Cameroon, Colombia, Côte d’Ivoire, Kuwait, Nigeria, Peru, Rwanda and Zambia. For more information, please email: communications@ihstowers.com or visit: www.ihstowers.com
About Centennial Towers: Centennial Towers is an independent developer, owner and operator of wireless communications towers in Latin America, with current operations in Mexico consisting of approximately 800 towers. For more information, please visit: www.centennialsites.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210411005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
